Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

Original languageEnglish (US)
Pages (from-to)257-258
Number of pages2
JournalNature Reviews Nephrology
Volume8
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Hyperkalemia
Hypertension
Renin-Angiotensin System
Acute Kidney Injury
Meta-Analysis
Safety
Incidence
Research
aliskiren
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Hypertension : RAS blockade, hyperkalemia and AKI-look and you will find. / Toto, Robert D.

In: Nature Reviews Nephrology, Vol. 8, No. 5, 05.2012, p. 257-258.

Research output: Contribution to journalArticle

@article{25f7b3280a8c438f94154a4f062ad40f,
title = "Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find",
abstract = "Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.",
author = "Toto, {Robert D.}",
year = "2012",
month = "5",
doi = "10.1038/nrneph.2012.62",
language = "English (US)",
volume = "8",
pages = "257--258",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Hypertension

T2 - RAS blockade, hyperkalemia and AKI-look and you will find

AU - Toto, Robert D.

PY - 2012/5

Y1 - 2012/5

N2 - Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

AB - Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

UR - http://www.scopus.com/inward/record.url?scp=84860300791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860300791&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2012.62

DO - 10.1038/nrneph.2012.62

M3 - Article

C2 - 22473512

AN - SCOPUS:84860300791

VL - 8

SP - 257

EP - 258

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 5

ER -